(IMA)
NCM – Real Time Price. Currency in USD
5.00
-0.40 (-7.41%)
At close: Mar 27, 2026, 4:00 PM EDT
5.00
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
5.00
-0.40 (-7.41%)
At close: Mar 27, 2026, 4:00 PM EDT
5.00
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-03-17 | 8-K | d56716d8k.htm |
| 2026-03-10 | S-8 | d107848ds8.htm |
| 2025-11-19 | 8-K | d834017d8k.htm |
| 2025-10-29 | 8-K | d24830d8k.htm |
| 2025-10-22 | 8-K | d55570d8k.htm |
| 2025-10-10 | 8-K | d25863d8k.htm |
| 2025-09-11 | CORRESP | filename1.htm |
| 2025-09-08 | S-1 | d931520ds1.htm |
| 2025-08-12 | 8-K/A | d655327d8ka.htm |
| 2025-08-05 | 8-K | d88091d8k.htm |